Sheybani Arsham

Four-year results of a minimally invasive transscleral glaucoma gel stent implantation in a prospective multi-centre study.

The XEN-GGM resulted in lower IOP and a reduction in medications from baseline over 4 years of follow-up.

American Glaucoma Society Position Paper: Microinvasive Glaucoma Surgery.

) merged the material into a cohesive draft. This draft was shared with the AGS Executive Committee and other members of the AGS Board of Directors for additional input.

Gel Stent Versus Trabeculectomy: The Randomized, Multicenter, Gold-Standard Pathway Study (GPS) of Effectiveness and Safety at 12 Months.

At month 12, the gel stent was statistically noninferior to trabeculectomy, per the percentage of patients achieving ≥20% IOP reduction from baseline without medication increase, clinical hypotony, vision loss to counting fingers, or SSI.

Reticular Corneal Edema or Corneal Honeycombing in Eyes Treated With Netarsudil: A Case Series.

02%) regardless of prior corneal edema status. In our experience, the reticular changes resolve upon cessation of netarsudil.

Corneal endothelial safety profile in minimally invasive glaucoma surgery.

Through 5 years postoperative, there were no differences in proportion of eyes with significant ECL or mean ECD between the iStent inject and control groups.

Reoperation Rates and Disease Costs for Primary Open-Angle Glaucoma Patients in the United States Treated with Incisional Glaucoma Surgery.

More than one-fourth of patients with POAG treated with incisional surgery underwent additional procedures to address index surgery failure within 5 years.

Compositional Analysis of Extracellular Aggregates in the Eyes of Patients With Exfoliation Syndrome and Exfoliation Glaucoma.

This analysis verified the presence of suspected XFM proteins and identified novel components.

Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma.

Implantation of iStent inject during phacoemulsification in patients with mild-to-moderate POAG did not produce any device-related complications or ECD safety concerns compared to phacoemulsification alone through 60 months.

Increased Aqueous Humor GDF15 Is Associated with Worse Visual Field Loss in Pseudoexfoliative Glaucoma Patients.

AH GDF15 is detectable in patients with PXG and POAG.

Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants.

The MGI was noninferior to the BGI in lowering IOP.

Consultation Section: Glaucoma. July consultation #2.

Left-Right Determination Factor 2 (LEFTY2) Is an Aqueous Humor Biomarker for Exfoliation Glaucoma.

LEFTY2 is a promising AH biomarker for XFG. Its clinical value may be limited by accessibility, OD/OS discordance, and interpatient variability. Its role in XFG pathogenesis requires further study.

January consultation #5.

Consultation Section: Glaucoma. July consultation #3.

Biocompatibility of a Novel Microfistula Implant in Nonprimate Mammals for the Surgical Treatment of Glaucoma.

In nonprimate mammals, the material composing the microfistula implant and the implant itself do not induce significant inflammation or tissue reaction.

Advancing the Economic Assessment of Microinvasive Glaucoma Surgery.

Early Clinical Results of a Novel Ab Interno Gel Stent for the Surgical Treatment of Open-angle Glaucoma.

The XEN140 gel stent lowers IOP with few complications when implanted for the surgical treatment of open-angle glaucoma.

Effect of endocyclophotocoagulation on refractive outcomes in angle-closure eyes after phacoemulsification and posterior chamber intraocular lens implantation.

In this study, patients with PACS, PAC, or PACG having phacoemulsification and IOL implantation with ECP had decreased predictability of the postoperative refraction and a small myopic shift compared with those without ECP.

Author Response: Dimensional and Flow Properties of the EX-PRESS Glaucoma Drainage Device.

Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: Pilot study.

Cataract surgery combined with implantation of the gelatin stent resulted in a significant reduction in IOP in eyes with OAG.

July consultation #7.

Fluid Dynamics of a Novel Micro-Fistula Implant for the Surgical Treatment of Glaucoma.

Under flow testing, the XEN micro-fistula implant was able to maintain backpressure above numerical hypotony levels without the use of complex valve systems.

December consultation #2.